Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRV9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,673
Award facts
- Contract value 100% obligated
- $25,673.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,673.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on January 21, 2026. The delivery order procures 266 mg/20 mL vials of EXPAREL, a specialty surgical anesthetic product, with an ultimate completion date of February 11, 2026. This award was issued under a firm fixed-price structure with no set-aside designation, allowing DMS Pharmaceutical Group to compete directly against other qualified vendors. The contract is funded by the DLA's Medical Supply Chain division to support Department of Defense pharmaceutical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, positioning the company as a critical regional pharmaceutical supplier for military healthcare facilities worldwide. As a PPV-G GEN V prime vendor contractor, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceuticals, biologics, and medical consumables to support recurring DoD medical supply needs. The company has demonstrated substantial federal contracting activity and consistent performance across multiple therapeutic categories, leveraging its small business status while maintaining competitive capability in unrestricted federal procurement.
Quick answers
Who was awarded contract SPE2DR26FCRV9?
SPE2DR26FCRV9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FCRV9 worth?
The government has obligated $25,673 on SPE2DR26FCRV9.
Is contract SPE2DR26FCRV9 an order under another contract?
Yes. SPE2DR26FCRV9 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRV9 competed?
The extent of competition for SPE2DR26FCRV9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award